Press release
Alexion Pharmaceuticals "Eculizumab" Market size expansion of Several Folds by 2034
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Eculizumab (Alexion Pharmaceuticals) providing insights into the drug market landscape and market forecast of Eculizumab upto 2034. The report, titled "Eculizumab Sales Forecast, and Market Size Analysis - 2034" is now available for review and analysis.
Are you interested in finding out the projected market size of Eculizumab in 2034? Eculizumab Market Forecast
https://www.delveinsight.com/report-store/eculizumab-sales-forecast-and-market-size-analysis [https://www.delveinsight.com/report-store/eculizumab-sales-forecast-and-market-size-analysis?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Key Factors Driving Eculizumab Growth
1. Market Share Gains and New Patient Starts
*
Eculizumab has been a cornerstone complement-inhibitor biologic, capturing significant market share in the treatment of rare complement-mediated disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) since its launch. Its early first-to-market leadership established strong physician familiarity and high uptake among eligible patients.
*
Over time, expanded approvals into additional indications including generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) have broadened its patient base and driven continued new patient starts as diagnosis rates increase globally.
*
As a high-cost orphan biologic, adoption has also been influenced by reimbursement policies and healthcare access frameworks, particularly in developed markets with strong rare disease programs, contributing to sustained prescription volumes.
2. Expansion Across Key Indications
*
Paroxysmal Nocturnal Hemoglobinuria (PNH): Eculizumab remains a key treatment option for reducing intravascular hemolysis and improving quality of life in PNH patients.
*
Atypical Hemolytic Uremic Syndrome (aHUS): The drug is approved to inhibit complement-mediated microangiopathy in aHUS, another rare, life-threatening condition.
*
Generalized Myasthenia Gravis (gMG): Indicated for adults and, following recent regulatory updates, pediatric patients aged greater than or equal to 6 years with AChR antibody-positive gMG, addressing a challenging neuromuscular disorder.
*
Neuromyelitis Optica Spectrum Disorder (NMOSD): Expansion into NMOSD further broadens clinical utility in autoimmune neurologic disease.
The Eculizumab Market Report offers projected sales forecasts for Eculizumab for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Alexion Pharmaceuticals's Eculizumab is serving as a beacon of hope for the patients suffering from the Paroxysmal Nocturnal Hemoglobinuria.
What is Eculizumab Prescribed for?
Eculizumab is a monoclonal antibody medication used to treat several rare and serious disorders caused by overactivation of the complement system, a part of the immune system. It works by inhibiting the C5 complement protein, helping prevent damage to blood cells and tissues.
Conditions Treated with Eculizumab
*
Paroxysmal Nocturnal Hemoglobinuria (PNH): Used to reduce the destruction of red blood cells (hemolysis) and lower the risk of blood clots.
*
Atypical Hemolytic Uremic Syndrome (aHUS): Helps prevent blood clot formation in small blood vessels, protecting kidney function.
*
Generalized Myasthenia Gravis (gMG): Prescribed for adults with anti-acetylcholine receptor antibody-positive gMG to improve muscle strength and reduce symptoms.
*
Neuromyelitis Optica Spectrum Disorder (NMOSD): Used in patients who test positive for aquaporin-4 antibodies to reduce relapse risk.
What Eculizumab is used for:
*
Treatment of Paroxysmal Nocturnal Hemoglobinuria: Helps address the genetic cause of the disorder by enabling the body to produce Factor IX, a clotting protein missing in these patients.
*
Reducing bleeding episodes: Lowers the frequency of spontaneous or injury-related bleeding events.
*
Decreasing dependence on regular infusions: Many patients who receive Eculizumab may reduce or eliminate the need for routine Factor IX replacement treatments.
The report extensively covers the details and developments related to Eculizumab, capturing important highlights on developmental pipeline, regulatory status and special designations of Eculizumab, route of administration, safety and efficacy details.
Eculizumab Market Assessment
This report provides a detailed market assessment of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2034.
Eculizumab Clinical Assessment
The report provides the clinical trials information of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria covering trial interventions, trial conditions, trial status, start and completion dates. The report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against Eculizumab? Eculizumab Drugs Insights [https://www.delveinsight.com/report-store/eculizumab-sales-forecast-and-market-size-analysis?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Eculizumab Recent Developments in the Treatment Landscape
EPYSQLI (eculizumab), a biosimilar referencing Soliris, was launched in the United States in 2025 through a strategic collaboration between Teva Pharmaceuticals and Samsung Bioepis. The introduction of this biosimilar aims to improve patient access and provide potential cost savings for individuals being treated for Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), and adult Generalized Myasthenia Gravis (gMG).
The U.S. Food and Drug Administration approved Bkemv (eculizumab) as the first interchangeable biosimilar to Soliris for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). This approval is expected to expand patient access in the United States while increasing market competition.
Expanded Indications:
The U.S. Food and Drug Administration approved an expanded indication for Soliris to treat pediatric patients with Generalized Myasthenia Gravis who are anti-AChR antibody-positive and aged 6 years or older, thereby extending therapeutic options to a younger patient population.
India Market Launch (2025):
AstraZeneca Pharma India announced its plans to introduce Soliris (eculizumab) in India in August 2025 following regulatory approval earlier in the year, representing a significant expansion into the Indian market.
Furthermore, local regulatory authorities approved a post-marketing surveillance study of Soliris in India, reflecting continued efforts to evaluate its safety profile and support real-world clinical use.
Eculizumab Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Eculizumab.
Eculizumab Market Size in the US
A dedicated section of the report focuses on the expected market size of Eculizumab for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
Key Highlights of Eculizumab:
*
The report contains forecasted sales of Eculizumab for indication till 2034.
*
Comprehensive coverage of the late-stage emerging therapies for Paroxysmal Nocturnal Hemoglobinuria.
*
The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Stay ahead in competition by leveraging insights on Eculizumab market Report: Download Eculizumab Market Report [https://www.delveinsight.com/report-store/eculizumab-sales-forecast-and-market-size-analysis?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Why you should buy Eculizumab Market Report:
*
The report provides future market assessments for Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
*
Leading Eculizumab for Paroxysmal Nocturnal Hemoglobinuria forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Eculizumab
*
Discover the competitive landscape of Eculizumab through 7MM
*
Get a Thorough Analysis of the Eculizumab Development pipeline, Safety & Efficacy of the Eculizumab, and ROA
*
Thorough Eculizumab market forecast will help understand how drug is competing with other emerging Eculizumab
*
Get analysis of the Eculizumab clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
*
Drug Market forecasts are calculated after taking into consideration KOL viewpoints
Related Reports By DelveInsight:
Paroxysmal Nocturnal Hemoglobinuria Pipeline
DelveInsight's, "Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight, 2026 [https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alexion-pharmaceuticals-eculizumab-market-size-expansion-of-several-folds-by-2034]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alexion Pharmaceuticals "Eculizumab" Market size expansion of Several Folds by 2034 here
News-ID: 4417206 • Views: …
More Releases from ABNewswire
Orlando Chiropractor Dr. Guillermo J. Nazario Offers DRX9000 Spinal Decompressio …
Mattia Spinal Care & Rehab Center highlights non-surgical spinal decompression technology for Orlando-area patients experiencing disc-related back pain, neck pain and sciatica.
ORLANDO, FL - Friday, September 25, 2026 - Mattia Spinal Care & Rehab Center, led by Guillermo J. Nazario, D.C., is highlighting the availability of DRX9000 True Non-Surgical Spinal Decompression for Orlando-area patients dealing with chronic low back pain, sciatica and certain disc-related conditions.
The Orlando chiropractic [https://theorlandochiropractor.com/] and rehabilitation…
Prime Dumpster Expands Dumpster Rental in Jackson, MS, to Meet Regional Industri …
Prime Dumpster is a leading facilitator of waste management services, offering dumpster rentals and comprehensive site services for construction projects, residential cleanouts, commercial facilities, and events. With a focus on customer satisfaction and tailored solutions, Prime Dumpster helps clients across the United States arrange the dumpster rental services they need.
Jackson, MS - September 25, 2026 - Prime Dumpster is expanding dumpster rental in Jackson, MS, bringing roll-off container services to…
Iron Deficiency Anemia Market: Rising Disease Burden, Advancing Iron Replacement …
The Iron Deficiency Anemia (IDA) market is witnessing continued evolution, driven by the substantial prevalence of iron deficiency anemia, increasing recognition of disease burden among women and patients with chronic conditions, the limitations of conventional oral iron products, and growing adoption of advanced oral and intravenous iron replacement therapies.
(Albany, New York) - September 25, 2026 - The Iron Deficiency Anemia (IDA) market is witnessing continued evolution, driven by the substantial…
Metastatic HR+/HER2 Breast Cancer Market is Projected to Grow at 8% CAGR by 2036 …
The market dynamics for Metastatic HR+/HER2 Breast Cancer are witnessing significant growth driven by the rising patient pool, continued reliance on endocrine therapy and CDK4/6 inhibitors, expansion of targeted treatment options, increasing adoption of next-generation selective estrogen receptor degraders (SERDs), and growing use of antibody-drug conjugates (ADCs) and pathway-specific therapies.
(Albany, New York) - September 25, 2026 The market dynamics for Metastatic HR+/HER2 Breast Cancer are witnessing significant growth driven by…
More Releases for Eculizumab
Soliris (Eculizumab) Market Progress: Advancing Rare Disease Treatment Through C …
The global Soliris (Eculizumab) Market is witnessing steady expansion as healthcare systems increasingly prioritize advanced therapies for rare, life-threatening complement-mediated diseases. Soliris (Eculizumab) has established itself as a leading biologic treatment for conditions such as atypical Hemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH), offering targeted therapeutic benefits that improve patient outcomes and quality of life. The market continues to evolve with greater awareness of rare diseases, expanding diagnostic…
Atypical Hemolytic Uremic Syndrome Market Size in the 7MM was USD 1,300 million …
DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as Atypical Hemolytic Uremic Syndrome therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Atypical Hemolytic Uremic Syndrome Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @…
Soliris (Eculizumab) Market Size, Trends, And Forecast to 2033 Alexion
Soliris (Eculizumab) is a monoclonal antibody that inhibits the complement protein C5, a key part of the complement cascade, preventing its cleavage into C5a and C5b. This action effectively blocks the formation of the membrane attack complex (MAC), which is implicated in the destruction of red blood cells and tissue damage in certain autoimmune and inflammatory diseases. It is FDA-approved for rare, life-threatening conditions such as paroxysmal nocturnal hemoglobinuria (PNH),…
Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size 2034 | Alexion Pharmaceuti …
DelveInsight's "Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Paroxysmal Nocturnal Hemoglobinuria Market Research Report
• According to Schubert et al. (2022), Paroxysmal Nocturnal Hemoglobinuria is a very rare…
2030 Projections: Eculizumab Market to Deliver Dynamic Progression Upto Forecast …
This research report provides an overview and forecast of the Eculizumab Market for the years 2023 to 2030, including product specifications, technological developments, and key manufacturers. The research explores market obstacles like market demand, market share for the industry, CAGR, current market trends, and competitive vendor strategies. The research identifies and manages the several Eculizumab market growth factors needed for a successful operation. This report is comprehensively and…
Eculizumab Market to Show Incredible Growth and Forecast by 2028 | Segment, Priv …
Industry Research Report On Eculizumab Market Quantitative And Qualitative Analysis
The latest research report on Eculizumab Market was conducted across a variety of industries in various regions to provide a report that has data surpassing 100+ pages. The report offers a mixture of qualitative and quantifiable information focusing on aspects such as key market developments, industry and competitors' challenges in gap analysis, and new opportunities in the Eculizumab market. Various leaders…
